Medicamen Biotech Limited — Important, 19-02-2025: General Updates

Medicamen Biotech Limited has entered into a significant Manufacturing & Supply Agreement with a leading pharma distributor and marketing company in the US and Europe. This international collaboration spans a term of 10 years and involves the contract manufacturing of the partner’s products according to their technical specifications. The initial consideration includes a 25% payment upon signing the agreement, leveraging Medicamen’s USFDA-approved Oncology Unit for enhanced manufacturing capabilities and R&D strengths. This strategic tie-up is expected to provide custom manufacturing services, potentially increasing revenue and market reach. Investors should note the positive implications for future growth opportunities in the pharma sector.